Natalie C. Holles - 11 Apr 2024 Form 4 Insider Report for Third Harmonic Bio, Inc. (THRD)

Role
CEO, Director
Signature
/s/ Christopher Murphy, Attorney-in-Fact
Issuer symbol
THRD
Transactions as of
11 Apr 2024
Net transactions value
-$108,270
Form type
4
Filing time
15 Apr 2024, 16:14:15 UTC
Previous filing
05 Jan 2024
Next filing
10 May 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction THRD Common Stock Options Exercise $56,944 +13,558 +1.1% $4.20 1,232,394 11 Apr 2024 Direct
transaction THRD Common Stock Sale $165,214 -13,558 -1.1% $12.19* 1,218,836 11 Apr 2024 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction THRD Employee Stock Option (right to buy) Options Exercise $0 -13,558 -2.9% $0.000000 454,076 11 Apr 2024 Common Stock 13,558 $4.20 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on [Month XX, 2023].
F2 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.15 to $12.31 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 6.25% of the total shares vested on May 17, 2022, and thereafter 6.25% of the total shares underlying the award shall vest in equal quarterly installments until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.